2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Sarcoma
1
Genitourinary
1
CNS
1
Conditions
Glioblastoma
5
Lung Neoplasms
4
Head and Neck Neoplasms
4
Breast Neoplasms
4
Sarcoma
3
Pancreatic Neoplasms
3
Glioma
3
Brain Neoplasms
3
Virus Diseases
2
Urinary Bladder Neoplasms
2
Stomach Neoplasms
2
Ovarian Neoplasms
2
Neuroectodermal Tumors
2
Nervous System Diseases
2
Neoplasms, Neuroepithelial
2
Neoplasms, Nerve Tissue
2
Neoplasms
2
Melanoma
2
Liver Neoplasms
2
Gliosarcoma
2
Colorectal Neoplasms
2
Carcinoma
2
Uterine Cervical Neoplasms
1
Small Cell Lung Carcinoma
1
Pharyngeal Neoplasms
1
Otorhinolaryngologic Neoplasms
1
Nose Neoplasms
1
Neoplasms, Glandular and Epithelial
1
Neoplasms, Germ Cell and Embryonal
1
Neoplasms by Histologic Type
1
Interventions
pembrolizumab
185
Gemcitabine
170
Paclitaxel
152
Carboplatin
137
Bevacizumab
128
Surveys and Questionnaires
118
Cisplatin
115
Docetaxel
114
Blood Specimen Collection
110
Cyclophosphamide
109
Exercise
108
Nivolumab
98
Fluorouracil
90
Capecitabine
86
Dexamethasone
81
Radiotherapy
80
Irinotecan
74
Standard of Care
69
Pemetrexed
68
Oxaliplatin
68
Leucovorin
64
Drug Therapy
64
Cetuximab
60
Erlotinib Hydrochloride
56
Sorafenib
53
atezolizumab
52
Ipilimumab
51
Doxorubicin
50
trametinib
47
Interviews as Topic
47
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Neoplasms
×
Oncolytic Virotherapy
×
Clear all
NCT02798406
2021-07-15
CAPTIVE
DNAtrix, Inc.
Phase 2
Completed
49 enrolled
NCT01438112
2021-04-14
BOND
CG Oncology, Inc.
Phase 2/3
Terminated
22 enrolled